[SAN FRANCISCO, USA – May 12th 2025] The animal longevity industry is achieving unprecedented breakthroughs, according to a new 350-page ClearView Market Insights report. The market is projected to grow at a CAGR of 33.7%, reaching USD 22.6 billion by 2032, thus redefining pet lifespans.
Request Sample @ https://clearviewmarketinsights.com/report-details/animal-longevity-medicine/
Key Industry Shifts
- Clinical Validation
- LOY-002 Trial Results:
- 28% lower mortality in senior dogs
- 1.8 year median lifespan extension
- Telomerase Therapy:
- Restores immune function in aging canines
- Economic Impacts
- Pet Owner Spending:
- Average $2,800/year on longevity regimens
- Insurance Premiums:
- 22% lower for treated animals
- Mainstream Adoption
- Veterinary Protocols:
- 60% of AAHA clinics now offer longevity panels
- Consumer Demand:
- Waitlists exceed 18 months at specialty centers
Executive Insights
- Celine Halioua, Loyal CEO:
"We're not just adding years to life—we're adding life to years." - Daniel Oliver, Rejuvenate Bio:
"Our gene therapy essentially resets the aging clock."
Future Projections
- 2028: First FDA approval for lifespan extension
- 2030: Routine epigenetic reset at middle age
- 2032: 25% of senior pets on treatment
For more insights, visit https://clearviewmarketinsights.com/report-store
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
